BACKGROUND: A low CD4/CD8 ratio in human immunodeficiency virus (HIV)-infected individuals despite effective antiretroviral therapy (ART) reflects ongoing immune activation and has been linked to a higher risk of non-AIDS morbidity and mortality. Our aim was to describe the proportion of individuals with a persistent CD4/CD8 ratio <1 despite long-term viral suppression and to determine associated risk factors. METHODS: This cross-sectional study was conducted in 2012 in a single clinical center. HIV type 1 (HIV-1)-infected individuals were eligible if they had a plasma HIV-1 RNA level <50 copies/mL for at least 2 years on a stable ART regimen. Logistic regression was used to identify risk factors for a persistent CD4/CD8 ratio <1. RESULTS: We enrolled 719 individuals with a median CD4/CD8 ratio of 0.8 (interquartile range [IQR], 0.6-1.1), CD4 and CD8 T-cell counts of 565 (IQR, 435-742) cells/µL and 727 (IQR, 530-991) cells/µL respectively, and viral suppression for 5.4 (IQR, 3.3-9.1) years. Cytomegalovirus (CMV) serology was positive in 564 of 645 individuals (87%). Persistent CD4/CD8 ratio <1 was observed in 471 patients (66%). The following factors were independently associated with a CD4/CD8 ratio <1: CMV seropositivity (odds ratio [OR], 1.9 [95% confidence interval {CI}, 1.1-3.1]), ART initiation before 1997 (OR, 1.9 [95% CI, 1.2-3.0] compared with 2002 or later), a lower CD4 T-cell nadir (OR, 0.7 [95% CI, .7-.8] per log2 increment), and shorter duration of viral suppression (OR, 0.6 [95% CI, .5-.8] per 5 years). CONCLUSIONS: Most HIV-infected individuals with long-term viral suppression still had a CD4/CD8 ratio <1. Early initiation and long-term effective ART appear to improve this ratio. CMV coinfection, which represents a potential target for therapeutic intervention, was strongly associated with a persistently suboptimal CD4/CD8 ratio.
BACKGROUND: A low CD4/CD8 ratio in human immunodeficiency virus (HIV)-infected individuals despite effective antiretroviral therapy (ART) reflects ongoing immune activation and has been linked to a higher risk of non-AIDS morbidity and mortality. Our aim was to describe the proportion of individuals with a persistent CD4/CD8 ratio <1 despite long-term viral suppression and to determine associated risk factors. METHODS: This cross-sectional study was conducted in 2012 in a single clinical center. HIV type 1 (HIV-1)-infected individuals were eligible if they had a plasma HIV-1 RNA level <50 copies/mL for at least 2 years on a stable ART regimen. Logistic regression was used to identify risk factors for a persistent CD4/CD8 ratio <1. RESULTS: We enrolled 719 individuals with a median CD4/CD8 ratio of 0.8 (interquartile range [IQR], 0.6-1.1), CD4 and CD8 T-cell counts of 565 (IQR, 435-742) cells/µL and 727 (IQR, 530-991) cells/µL respectively, and viral suppression for 5.4 (IQR, 3.3-9.1) years. Cytomegalovirus (CMV) serology was positive in 564 of 645 individuals (87%). Persistent CD4/CD8 ratio <1 was observed in 471 patients (66%). The following factors were independently associated with a CD4/CD8 ratio <1: CMV seropositivity (odds ratio [OR], 1.9 [95% confidence interval {CI}, 1.1-3.1]), ART initiation before 1997 (OR, 1.9 [95% CI, 1.2-3.0] compared with 2002 or later), a lower CD4 T-cell nadir (OR, 0.7 [95% CI, .7-.8] per log2 increment), and shorter duration of viral suppression (OR, 0.6 [95% CI, .5-.8] per 5 years). CONCLUSIONS: Most HIV-infected individuals with long-term viral suppression still had a CD4/CD8 ratio <1. Early initiation and long-term effective ART appear to improve this ratio. CMV coinfection, which represents a potential target for therapeutic intervention, was strongly associated with a persistently suboptimal CD4/CD8 ratio.
Authors: Davey M Smith; Masato Nakazawa; Michael L Freeman; Christy M Anderson; Michelli F Oliveira; Susan J Little; Sara Gianella Journal: Clin Infect Dis Date: 2016-09-06 Impact factor: 9.079
Authors: Jessica L Castilho; Megan Turner; Bryan E Shepherd; John R Koethe; Sally S Furukawa; Carmen E Bofill; Stephen Raffanti; Timothy R Sterling Journal: AIDS Res Hum Retroviruses Date: 2019-09-17 Impact factor: 2.205
Authors: Matteo Vassallo; R Fabre; J Durant; C Lebrun-Frenay; H Joly; M Ticchioni; F DeSalvador; A Harvey-Langton; B Dunais; M Laffon; J Cottalorda; P Dellamonica; C Pradier Journal: J Neurovirol Date: 2016-11-04 Impact factor: 2.643
Authors: Kathy Petoumenos; Jun Yong Choi; Jennifer Hoy; Sasisopin Kiertiburanakul; Oon Tek Ng; Mark Boyd; Reena Rajasuriar; Matthew Law Journal: Antivir Ther Date: 2017
Authors: Eshan U Patel; Sara Gianella; Kevin Newell; Aaron A R Tobian; Allison R Kirkpatrick; Fredrick Nalugoda; Mary K Grabowski; Ronald H Gray; David Serwadda; Thomas C Quinn; Andrew D Redd; Steven J Reynolds Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Timothy N Hoang; Justin L Harper; Maria Pino; Hong Wang; Luca Micci; Colin T King; Colleen S McGary; Julia B McBrien; Barbara Cervasi; Guido Silvestri; Mirko Paiardini Journal: J Virol Date: 2018-12-10 Impact factor: 5.103
Authors: Albert M Anderson; Josué Pérez-Santiago; Ziduo Zheng; Eugene Huang; Donald Franklin; Jennifer Iudicello; David J Moore; Ronald J Ellis; Robert K Heaton; Scott L Letendre Journal: AIDS Date: 2019-12-01 Impact factor: 4.632